Skip to content
Partnership for Safe Medicines
  • News
    • Diabetes & Weight-loss Injectables
    • Fake HIV Medications
    • PBMs
    • Botox / Botulism warning
    • Illegal Pill Presses
    • Fake Adderall
    • Poisonous cough syrup
    • Social Media & Fake Pills
    • Counterfeit Pill Crisis
  • Patients
    • Learn about Counterfeits and to Save Money Safely
    • The Drug Importation Debate
    • Drug Counterfeiters Get Light Sentences
    • Real Victims of Counterfeit Drugs
    • Talk to Your Family
    • HIV/HEPC Patients
    • Mexican Pharmacies
  • Professionals
    • Pharmacists
    • Doctors
    • Law Enforcement
    • Educators
    • Prosecution Document Library
    • Research On Drug Safety
  • Policy
    • Publications
    • Pharmaceutical Border Security
    • Drug Importation
    • PBM under-reimbursement
    • Illegal Pill Presses
    • Affordability Boards (PDABs)
    • Alternative funding programs (AFPs)
    • Pharmacy-to-pharmacy marketplaces
    • FOIA-ed Materials
    • Events, briefings, and op-eds
  • About Us
    • Join Our Mailing List
    • Members
    • PSM Leadership
    • Press Releases
    • Contact Us
Document Tags: Case: 1:24-cv-04443, Complaint, compounding, GenericOzempic.com, GLP-1 lawsuit, illinois, Novo Nordisk, semaglutide
Return to list

United States District Court
Northern District of Illinois

Novo Nordisk Inc. v. Green Care Professional Services, P.C. dba GenericOzempic.com and GCM Partners, LLC

Complaint

May 30, 2024

Read the document.

<a href="https://www.safemedicines.org/wp-content/uploads/2019/09/Novo-Nordisk-v-GenericOzempic-Complaint.pdf">Novo Nordisk v GenericOzempic.com</a><br>Filed in Illinois May 30, 2024.
© 2003-2023 Partnership for Safe Medicines
Click here to contact us.
Facebook Twitter Linkedin Youtube Instagram Email
Scroll To Top